Page last updated: 2024-11-04

cgp 12177

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CGP 12177 : A benzimidazole that is benzimidazol-2-one substituted at position 4 by a 3-(tert-butylamino)-2-hydroxypropoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2687
CHEMBL ID420746
CHEBI ID73288
SCHEMBL ID2016211
MeSH IDM0103614

Synonyms (57)

Synonym
BRD-A34706053-003-01-9
gtpl532
DIVK1C_006872
SPECTRUM_001907
81047-99-6
LOPAC0_000372
4-[3-(tert-butylamino)-2-hydroxypropoxy]-2,3-dihydro-1h-1,3-benzodiazol-2-one hydrochloride
[3h]cgp 12177
bdbm25747
cgp12177
cgp12177a
NCGC00025024-03
cgp-12177
4-(3-tert-butylamino-2-hydroxypropoxy)benzimidazol-2-one
cgp 12177
tbhpbo
cgp 12177a
2h-benzimidazol-2-one, 4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,3-dihydro-
KBIOGR_001194
KBIO2_005006
KBIO1_001816
KBIO2_002438
KBIO2_007574
KBIOSS_002444
SPECTRUM4_000777
SPECPLUS_000776
cgp-12177a hydrochloride
NCGC00025024-02
NCGC00015184-05
CHEMBL420746
chebi:73288 ,
L000166
4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydrobenzimidazol-2-one
bdbm50027879
CCG-204467
4-[3-(tert-butylamino)-2-hydroxypropoxy]-1,3-dihydro-2h-benzimidazol-2-one
NCGC00015184-04
NCGC00015184-03
r89umz82mj ,
unii-r89umz82mj
(+/-)-cgp-12177a hydrochloride
gtpl5387
[3h]cgp12177
[3h]-cgp12177
4-[3-(tert-butylamino)-2-hydroxypropoxy]-2,3-dihydro-1h-1,3-benzodiazol-2-one
(+/-)-cgp-12177
4-(3-(tert-butylamino)-2-hydroxypropoxy)-1,3-dihydrobenzimidazol-2-one
cgp-12177, (+/-)-
SCHEMBL2016211
4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2h-benzimidazol-2-one
FT-0708718
Q27075889
SDCCGSBI-0050360.P003
NCGC00015184-08
DTXSID901001733
7-[3-(tert-butylamino)-2-hydroxypropoxy]-1h-benzimidazol-2-ol
2h-benzimidazol-2-one, 4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-

Research Excerpts

Overview

CGP 12177 is a beta-adrenergic receptor (AR) ligand. It has been used to characterize the beta3-AR and the putative beta4-AR.

ExcerptReferenceRelevance
"CGP 12177 is a beta-adrenergic receptor (AR) ligand that has been used to characterize the beta3-AR and the putative beta4-AR. "( beta1-adrenergic receptors mediate beta3-adrenergic-independent effects of CGP 12177 in brown adipose tissue.
Granneman, JG; Konkar, AA; Zhai, Y, 2000
)
1.98

Actions

ExcerptReferenceRelevance
"CGP 12177 induced an increase in intracellular calcium concentration in pressurized arteries loaded with Fura PE-3 and precontracted with PGF(2alpha)."( Role of alpha-adrenergic receptors in the effect of the beta-adrenergic receptor ligands, CGP 12177, bupranolol, and SR 59230A, on the contraction of rat intrapulmonary artery.
Guibert, C; Ivorra, MD; Leblais, V; Marthan, R; Muller, B; Pourageaud, F, 2004
)
1.27

Treatment

Pretreatment with CGP 12177A, a beta 3-selective agonist, also reduced adenylyl cyclase activity in transfected 293 cells.

ExcerptReferenceRelevance
"Both CGP 12177 and RA treatment decreased levels of leptin mRNA to a similar extent."( Differential effects of retinoic acid on uncoupling protein-1 and leptin gene expression.
Kumar, MV; Scarpace, PJ, 1998
)
0.76
"Pretreatment with CGP 12177A, a beta 3-selective agonist, also reduced beta 3-stimulated adenylyl cyclase activity in transfected 293 cells."( Influence of cell type upon the desensitization of the beta 3-adrenergic receptor.
Chaudhry, A; Granneman, JG, 1994
)
0.61

Dosage Studied

ExcerptRelevanceReference
" The pA2 values of the beta adrenergic antagonists propranolol, metoprolol and atenolol were calculated from the rightward shifts that they impose on dose-response curves of both l-isoproterenol and CGP12177."( Multiple beta adrenergic receptor subclasses mediate the l-isoproterenol-induced lipolytic response in rat adipocytes.
Van Liefde, I; Van Witzenburg, A; Vauquelin, G, 1992
)
0.28
" Lactate reduced isoproterenol-induced lipolysis in a dose-response fashion and such inhibition became significant only at 16 mmol/l lactate."( Influence of lactate on isoproterenol-induced lipolysis and beta-adrenoceptors distribution in human fat cells.
Cardone, F; Cignarelli, M; Corso, M; De Pergola, G; Di Paolo, S; Garruti, G; Giorgino, R; Nardelli, G, 1989
)
0.28
" The dose-response curve of adenylate cyclase to the GTP analogue, GppNHp, was modified by 5HT, which promotes a significantly higher maximal response without altering the potency of GppNHp."( Heterologous sensitization of adenylate cyclase activity by serotonin in the rat cerebral cortex.
Brunello, N; Perez, J; Racagni, G; Rovescalli, AC; Steardo, L; Vitali, S, 1993
)
0.29
" Moreover, metoprolol and atenolol, two beta 1- AR- selective antagonists, shift the isoproterenol dose-response curve to the right with high potency as well."( No functional atypical beta-adrenergic receptors in human omental adipocytes.
Van Ermen, A; Van Liefde, I; Vauquelin, G, 1994
)
0.29
"The effect of propranolol dosing rate on beta-blockade was studied in human volunteers after administration of a conventional tablet and a sustained release capsule."( Dosing rate-dependent relationship between propranolol plasma concentration and beta-blockade.
Kashiwada, K; Ogata, H; Ohira, M; Someya, K; Takahashi, H, 1993
)
0.29
" With the dosage scheme applied, the density of beta-adrenoceptors was augmented 24 h after the first dose of DFP and decreased to about one half of control values after 5 days of treatment with DFP."( Biphasic changes in the density of muscarinic and beta-adrenergic receptors in cardiac atria of rats treated with diisopropylfluorophosphate.
Myslivecek, J; Trojan, S; Tucek, S, 1996
)
0.29
"003 mumol kg-1 shifted to the right the dose-response curve of prenalterol for its positive chronotropic effect."( Mediation of the positive chronotropic effect of CGP 12177 and cyanopindolol in the pithed rat by atypical beta-adrenoceptors, different from beta 3-adrenoceptors.
Malinowska, B; Schlicker, E, 1996
)
0.55
"In human subjects, chronic beta2-agonist dosing reduces mononuclear leukocyte (MNL) beta-adrenoceptor numbers."( In vivo quantification of human pulmonary beta-adrenoceptors: effect of beta-agonist therapy.
Hayes, MJ; Hughes, JM; Ind, PW; Jones, T; Qing, F; Rahman, SU; Rhodes, CG; Sriskandan, S, 1996
)
0.29
" Analysis of dose-response curves for isoproterenol and CGP-12177 revealed that neither basal nor stimulated AC activities nor 50% stimulatory concentration for these agonists was changed by T3 administration."( Effects of triiodothyronine administration on the adenylyl cyclase system in brown adipose tissue of rat.
Adli, H; Bazin, R; Perret, GY; Vassy, R, 1997
)
0.3
" This study assesses the effect of long-term beta2-agonist dosing on cardiac beta-adrenoceptors."( Effect of long-term beta2-agonist dosing on human cardiac beta-adrenoceptor expression in vivo: comparison with changes in lung and mononuclear leukocyte beta-receptors.
Hayes, MJ; Hughes, JM; Ind, PW; Jones, T; Qing, F; Rahman, SU; Rhodes, CG,
)
0.13
" Also, the higher gene dosage resulting from multiple insertions of the expression cassette led to an improvement in production by a factor of two for both receptors."( Comparative biochemical and pharmacological characterization of the mouse 5HT5A 5-hydroxytryptamine receptor and the human beta2-adrenergic receptor produced in the methylotrophic yeast Pichia pastoris.
Haase, W; Michel, H; Reiländer, H; Weiss, HM, 1998
)
0.3
"The effect of dietary olive oil and fish oil on the lipolytic dose-response of the beta3-adrenergic agonists, epinephrine, isoproterenol, BRL-37344, and CGP-12177, in adipocytes was studied in pregnant and virgin rats either untreated or under hyperinsulinemic-euglycemic conditions."( Changes in dietary fatty acids modify the decreased lipolytic beta3-adrenergic response to hyperinsulinemia in adipocytes from pregnant and nonpregnant rats.
Amusquivar, E; Cacho, J; Herrera, E, 2000
)
0.31
" The dose-response relationships of the beta(3)-adrenoceptor agonists were challenged with the selective beta(3)-adrenoceptor antagonist 3-(2-ethylphenoxy)-1-[(1S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) or the beta(2)-adrenoceptor antagonist (-)propranolol."( Enhancement of memory consolidation in chicks by beta(3)-adrenoceptor agonists.
Gibbs, ME; Summers, RJ, 2001
)
0.31
"The present study has addressed the question of what is more important for the occurrence of adaptive changes observed in the organism treated with antidepressant drugs: a daily dosing of the drug or the period of time necessary for the plastic events to develop."( Delayed effects of antidepressant drugs in rats.
Dziedzicka-Wasylewska, M; Faron-Górecka, A; Kuśmider, M, 2006
)
0.33
" This pharmacological profile combined with clinical data is consistent with once a day dosing of vilanterol in the treatment of both asthma and chronic obstructive pulmonary disease (COPD)."( In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action.
Barrett, VJ; Emmons, AJ; Ford, AJ; Knowles, RG; Morrison, VS; Slack, RJ; Sturton, RG, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
beta-adrenergic antagonistAn agent that binds to but does not activate beta-adrenergic receptors thereby blocking the actions of endogenous or exogenous beta-adrenergic agonists. beta-Adrenergic antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches and anxiety.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
benzimidazolesAn organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
secondary amino compoundA compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID493107
arylsulfatase AHomo sapiens (human)Potency6.01201.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.12200.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency4.10920.02245.944922.3872AID488982
flap endonuclease 1Homo sapiens (human)Potency5.97280.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-2 adrenergic receptorHomo sapiens (human)Kd0.02440.00000.62888.9130AID1626022; AID1626023; AID1798580
Beta-1 adrenergic receptorHomo sapiens (human)EC50 (µMol)0.01230.00010.49146.0000AID739708
Beta-1 adrenergic receptorHomo sapiens (human)Kd0.03430.00010.803910.0000AID1798580
Beta-3 adrenergic receptorHomo sapiens (human)Kd0.03430.00010.76318.9130AID1798580
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
diet induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
regulation of sodium ion transportBeta-2 adrenergic receptorHomo sapiens (human)
transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-2 adrenergic receptorHomo sapiens (human)
smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
cell surface receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
endosome to lysosome transportBeta-2 adrenergic receptorHomo sapiens (human)
response to coldBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase A signalingBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of bone mineralizationBeta-2 adrenergic receptorHomo sapiens (human)
heat generationBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-2 adrenergic receptorHomo sapiens (human)
bone resorptionBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBeta-2 adrenergic receptorHomo sapiens (human)
negative regulation of smooth muscle contractionBeta-2 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of mini excitatory postsynaptic potentialBeta-2 adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of autophagosome maturationBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of lipophagyBeta-2 adrenergic receptorHomo sapiens (human)
cellular response to amyloid-betaBeta-2 adrenergic receptorHomo sapiens (human)
response to psychosocial stressBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of cAMP-dependent protein kinase activityBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of AMPA receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-2 adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineBeta-1 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
response to coldBeta-1 adrenergic receptorHomo sapiens (human)
heat generationBeta-1 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-1 adrenergic receptorHomo sapiens (human)
fear responseBeta-1 adrenergic receptorHomo sapiens (human)
regulation of circadian sleep/wake cycle, sleepBeta-1 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-1 adrenergic receptorHomo sapiens (human)
regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-1 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-1 adrenergic receptorHomo sapiens (human)
receptor-mediated endocytosisBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
diet induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
carbohydrate metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
generation of precursor metabolites and energyBeta-3 adrenergic receptorHomo sapiens (human)
energy reserve metabolic processBeta-3 adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
response to coldBeta-3 adrenergic receptorHomo sapiens (human)
heat generationBeta-3 adrenergic receptorHomo sapiens (human)
negative regulation of multicellular organism growthBeta-3 adrenergic receptorHomo sapiens (human)
eating behaviorBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeBeta-3 adrenergic receptorHomo sapiens (human)
brown fat cell differentiationBeta-3 adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayBeta-3 adrenergic receptorHomo sapiens (human)
positive regulation of cold-induced thermogenesisBeta-3 adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine-mediated vasodilation involved in regulation of systemic arterial blood pressureBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (18)

Processvia Protein(s)Taxonomy
amyloid-beta bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta2-adrenergic receptor activityBeta-2 adrenergic receptorHomo sapiens (human)
protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
adenylate cyclase bindingBeta-2 adrenergic receptorHomo sapiens (human)
potassium channel regulator activityBeta-2 adrenergic receptorHomo sapiens (human)
identical protein bindingBeta-2 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-2 adrenergic receptorHomo sapiens (human)
protein-containing complex bindingBeta-2 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-2 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
beta1-adrenergic receptor activityBeta-1 adrenergic receptorHomo sapiens (human)
protein bindingBeta-1 adrenergic receptorHomo sapiens (human)
PDZ domain bindingBeta-1 adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingBeta-1 adrenergic receptorHomo sapiens (human)
protein heterodimerization activityBeta-1 adrenergic receptorHomo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic membrane potentialBeta-1 adrenergic receptorHomo sapiens (human)
norepinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
protein bindingBeta-3 adrenergic receptorHomo sapiens (human)
beta3-adrenergic receptor activityBeta-3 adrenergic receptorHomo sapiens (human)
beta-3 adrenergic receptor bindingBeta-3 adrenergic receptorHomo sapiens (human)
protein homodimerization activityBeta-3 adrenergic receptorHomo sapiens (human)
epinephrine bindingBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusBeta-2 adrenergic receptorHomo sapiens (human)
lysosomeBeta-2 adrenergic receptorHomo sapiens (human)
endosomeBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-2 adrenergic receptorHomo sapiens (human)
Golgi apparatusBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
endosome membraneBeta-2 adrenergic receptorHomo sapiens (human)
membraneBeta-2 adrenergic receptorHomo sapiens (human)
apical plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneBeta-2 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-2 adrenergic receptorHomo sapiens (human)
receptor complexBeta-2 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-2 adrenergic receptorHomo sapiens (human)
early endosomeBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
Schaffer collateral - CA1 synapseBeta-1 adrenergic receptorHomo sapiens (human)
neuronal dense core vesicleBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-1 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
receptor complexBeta-3 adrenergic receptorHomo sapiens (human)
plasma membraneBeta-3 adrenergic receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1626024Binding affinity to inactive/G protein-uncoupled human beta2-AR by immobilized artificial membrane HPLC analysis2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID165856Biodistribution pattern of [123I]- ligand was evaluated in right atrial muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID166005Cerebral biodistribution pattern of [123I]- ligand was evaluated in hypothalamus of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165700Biodistribution pattern of [123I]- ligand was evaluated in left ventricular muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID166127Cerebral biodistribution pattern of [123I]- ligand was evaluated in kidney of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165693Biodistribution pattern of [123I]- ligand was evaluated in left atrial muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID166144Cerebral biodistribution pattern of [123I]- ligand was evaluated in thalamus of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165999Cerebral biodistribution pattern of [123I]- ligand was evaluated in frontal cortex of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID739708Partial agonist activity at human beta1 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation after 5 hrs2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.
AID165984Biodistribution pattern of [123I]- ligand was evaluated in spleen of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165842Biodistribution pattern of [123I]- ligand was evaluated in lung of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID166137Cerebral biodistribution pattern of [123I]- ligand was evaluated in striatum of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID1626022Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID166130Cerebral biodistribution pattern of [123I]- ligand was evaluated in pituitary gland of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID739707Partial agonist activity at human beta1 adrenoceptor expressed in CHOK1 cells assessed as induction of [3H]cAMP accumulation measured after 5 hrs relative to isoprenaline2013Journal of medicinal chemistry, May-23, Volume: 56, Issue:10
Synthesis and in vitro and in vivo characterization of highly β1-selective β-adrenoceptor partial agonists.
AID165863Biodistribution pattern of [123I]- ligand was evaluated in right ventricular muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID218848Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
Mapping of the beta 2-adrenoceptor on Chang liver cells. Differences between high- and low-affinity receptor states.
AID165849Biodistribution pattern of [123I]- ligand was evaluated in muscle of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165560Biodistribution pattern of [123I]- ligand was evaluated in blood of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165992Cerebral biodistribution pattern of [123I]- ligand was evaluated in cerebellum of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165674Biodistribution pattern of [123I]- ligand was evaluated in fat of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID165835Biodistribution pattern of [123I]- ligand was evaluated in liver of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID1626023Displacement of [3H]DHA from inactive/G protein-uncoupled human beta2-AR expressed in CHO cell membranes assessed as intrinsic Kd by liquid scintillation counting2016Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12
Uncoupling the Structure-Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding.
AID165681Biodistribution pattern of [123I]- ligand was evaluated in intestine of anesthetized rabbit after Intravenous injection of 50 uCi after 2 hr1996Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17
Synthesis and in vitro and in vivo characteristics of an iodinated analogue of the beta-adrenoceptor antagonist carazolol.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1997British journal of pharmacology, Jan, Volume: 120, Issue:2
Effects of (-)-RO363 at human atrial beta-adrenoceptor subtypes, the human cloned beta 3-adrenoceptor and rodent intestinal beta 3-adrenoceptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)2004Naunyn-Schmiedeberg's archives of pharmacology, May, Volume: 369, Issue:5
Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.
AID1347018Rat beta3-adrenoceptor (Adrenoceptors)1995European journal of pharmacology, Nov-30, Volume: 291, Issue:3
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1993Molecular pharmacology, Dec, Volume: 44, Issue:6
Structural and conformational features determining selective signal transduction in the beta 3-adrenergic receptor.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)1999European journal of pharmacology, Feb-19, Volume: 367, Issue:2-3
LK 204-545, a highly selective beta1-adrenoceptor antagonist at human beta-adrenoceptors.
AID1346312Mouse beta3-adrenoceptor (Adrenoceptors)1995European journal of pharmacology, Nov-30, Volume: 291, Issue:3
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
AID1346260Human beta1-adrenoceptor (Adrenoceptors)2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1346250Human beta2-adrenoceptor (Adrenoceptors)2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
AID1346297Human beta3-adrenoceptor (Adrenoceptors)1995European journal of pharmacology, Nov-30, Volume: 291, Issue:3
Carazolol: a potent, selective beta 3-adrenoceptor agonist.
AID17985803H-CGP 12177 Whole Cell Binding Assay from Article 10.1038/sj.bjp.0706048: \\The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.\\2005British journal of pharmacology, Feb, Volume: 144, Issue:3
The selectivity of beta-adrenoceptor antagonists at the human beta1, beta2 and beta3 adrenoceptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (543)

TimeframeStudies, This Drug (%)All Drugs %
pre-199098 (18.05)18.7374
1990's270 (49.72)18.2507
2000's144 (26.52)29.6817
2010's26 (4.79)24.3611
2020's5 (0.92)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.86 (24.57)
Research Supply Index6.34 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials9 (1.62%)5.53%
Reviews7 (1.26%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other540 (97.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Circadian Mechanisms of Cardiovascular Risk in Obesity [NCT03388788]Early Phase 116 participants (Actual)Interventional2018-05-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]